At AbbVie, we invest in neuroscience research that identifies
opportunities to help people who live with neurologic disorders. We
are advancing research and providing treatments across many neurologic
disorders, including Alzheimer’s disease, bipolar disorder, bipolar
depression, major depressive disorder, migraine, multiple sclerosis,
Parkinson’s disease, post-stroke spasticity, schizophrenia, stroke and
other central nervous system disorders.
We are committed to investing in research that identifies
opportunities for real modification, delivering pioneering science,
built on inevitable setbacks, that will make a meaningful difference
We have expanded our portfolio to include migraine to help those
living with and affected by this debilitating disease, which affects
one in seven people worldwide. We are committed to pursuing and
providing treatment options that reduce the frequency and severity of
headache and prevent migraine attacks.